Research programme: chimeric antigen receptor T cell therapeutics - City of Hope National Medical Center/Mustang Bio

Drug Profile

Research programme: chimeric antigen receptor T cell therapeutics - City of Hope National Medical Center/Mustang Bio

Alternative Names: CAR-T cells - Coronado/City of Hope; CAR-T cells - Mustang Bio; MB 103; MB 104; MB 105; MB-103 HER2 CAR; MB-104 CS1 CAR; MB-105 PSCA CAR

Latest Information Update: 14 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator City of Hope National Medical Center
  • Developer City of Hope National Medical Center; Mustang Bio
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Jun 2017 Preclinical trials in Cancer (Refractory metastatic disease) in USA (Intraventricular) (Mustang Bio and Fortress Biotech pipeline, June 2017)
  • 05 Jun 2017 MB 103, MB 104 and MB 105 licensed to Mustang Bio
  • 01 Feb 2017 Mustang Bio entered into an agreement with City of Hope to acquire intellectual property rights in patent applications related to the intraventricular and intracerebroventricular methods of delivering T-cells that express chimeric antigen receptor and patent applications related to engineered anti-prostate stem cell antigen antibodies for cancer detection and targeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top